Skip to main content

Year: 2024

FuelCell Energy Announces Fourth Quarter and Fiscal Year 2024 Results Conference Call on December 19, 2024 at 10 A.M. Eastern Time

DANBURY, Conn., Dec. 11, 2024 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (NASDAQ: FCEL) — announced the upcoming release of its fourth quarter and fiscal year 2024 results prior to the Stock Market Open on Thursday, December 19, 2024. FuelCell Energy management will subsequently host a conference call with investors beginning at 10:00 a.m. Eastern Time on Thursday, December 19, 2024, to discuss the results and provide a business update. Participants can access the live call via webcast on the Company website or by telephone as follows:The live webcast of this call and supporting slide presentation will be available at www.fuelcellenergy.com. To listen to the call, select ‘Investors’ on the home page, proceed to the ‘Events & Presentations’ page and then click on the ‘Webcast’ link under the December 19th earnings call...

Continue reading

Chart Industries, Inc. Announces $250 Million Share Repurchase Authorization

ATLANTA, Dec. 11, 2024 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) (“Chart”), a global leader in clean energy and industrial gas solutions, today announced that its Board of Directors has authorized a share repurchase program of up to $250.0 million of its common stock. Under the stock repurchase program, Chart may purchase shares of its common stock through various means, including open market transactions, block purchases, privately negotiated transactions or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The program may be modified, discontinued or suspended at any time without prior notice. We reiterate our financial policy of no share repurchases or material cash acquisitions until we are below 2.5 net leverage,...

Continue reading

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024. Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the agreement. Hepion also announced that its previously announced special meeting of its stockholders scheduled for December 12, 2024 has been cancelled and that it has withdrawn from consideration by its stockholders...

Continue reading

The Alkaline Water Company CEO Issues Open Letter to Shareholders on Progress Within Two Distinct Growth Opportunities

SCOTTSDALE, Ariz., Dec. 11, 2024 (GLOBE NEWSWIRE) — The Alkaline Water Company, Inc. (OTC: WTER), today issued an open letter from Ricky Wright, Chief Executive Officer, to shareholders discussing the Company’s progress to date with the advancement of the business model and the future plans for WTER. The full letter is published below: Dear Shareholders, I am excited to address our valued shareholders as I return to The Alkaline Water Company. From 2012 through 2022, we successfully established alkaline water as a recognized beverage category. Today, I am eager to share our path forward in this thriving billion-dollar market. The alkaline water market offers two distinct growth opportunities: pH-enhanced purified water and naturally alkaline spring waters. Both segments are experiencing strong consumer demand and remain highly...

Continue reading

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listings Phathom believes applicable law mandates a 10-year NCE exclusivity period (from date of first approval of drug containing vonoprazan) benefitting all vonoprazan-based products, with exclusivity until May 3, 2032FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the full...

Continue reading

Vera Bradley Announces Third Quarter Fiscal Year 2025 Results

Consolidated net revenues totaled $80.6 million Financial condition remains strong with no debt and approximately $89 million of liquidity Updates outlook for fiscal year ending February 1, 2025 FORT WAYNE, Ind., Dec. 11, 2024 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) today announced its financial results for the third quarter and nine months ended November 2, 2024. In this release, Vera Bradley, Inc. or “the Company” refers to the entire enterprise and includes both the Vera Bradley and Pura Vida brands. Vera Bradley on a stand-alone basis refers to the Vera Bradley brand. Third Quarter Comments Jackie Ardrey, Chief Executive Officer commented, “The third quarter was extremely challenging as we remained in the early stages of ‘Project Restoration’, our strategic initiative to transform our business model and transition...

Continue reading

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data shows robust remission and response efficacy rates in patients taking CAPLYTA Robust improvements in anxiety symptoms were also observed in patients taking CAPLYTA as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7) Pooled safety and tolerability data from Studies 501 and 502 show favorable safety and tolerability profile for CAPLYTA consistent with prior studies A post-hoc analysis from Study 403 in mixed features shows CAPLYTA significantly improved anhedonia symptoms as measured by the MADRS anhedonia factor score BEDMINSTER, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI),...

Continue reading

SUPERIOR GROUP OF COMPANIES TO PARTICIPATE IN SINGULAR RESEARCH’S 19th ANNUAL BEST OF THE UNCOVEREDS CONFERENCE

ST. PETERSBURG, Fla., Dec. 11, 2024 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) today announced that Mike Koempel, Chief Financial Officer, will participate Singular Research’s Virtual Conference on Thursday, December 12, 2024 and will present at 12:00 PM Eastern Time. The webinar will be available on the investor relations Events & Presentations page of the Company’s website at https://ir.superiorgroupofcompanies.com/presentations. About Superior Group of Companies, Inc. (SGC):Established in 1920, Superior Group of Companies is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across Healthcare Apparel, Branded Products and Contact Centers, each segment enables businesses to create extraordinary brand engagement experiences for their...

Continue reading

GlobeTopper Reports 37% MoM Revenue Growth to $4.05 Million, Driven by Strong Cryptocurrency Expansion and Digital Gift Card Demand

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) — Accredited Solutions, Inc. (OTC: ASII) (“Accredited Solutions” or the “Company”), the parent company of Diamond Creek Water and the wholly-owned subsidiary GlobeTopper, is excited to announce a record-breaking 37% month-over-month (MoM) growth in revenue for GlobeTopper, bringing its total to $4.05 million for the month. GlobeTopper, a leader in the B2B digital gift card space, partners with rewards programs, e-commerce platforms and fintech companies to distribute a wide portfolio of e-gift cards from prominent global retailers. While the company credits much of its success to the growing adoption of digital gift cards across retail and consumer markets, it also highlights the significant role that Bitcoin and cryptocurrency have played in driving growth. Recent...

Continue reading

L3Harris Awards CPI Aerostructures, Inc. Contract for Next Generation Jammer Low-Band Program

CPI to deliver Pod Structures to support airworthiness and design verification EDGEWOOD, N.Y., Dec. 11, 2024 (GLOBE NEWSWIRE) — CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU), a leading manufacturer of structural assemblies in both the commercial and military defense aerospace markets, announced today that it was awarded by L3Harris Technologies (NYSE: LHX) a contract not-to-exceed $12.1 million to deliver airborne pod structures. This contract supports L3Harris’ delivery of operational prototype pods to the U.S. Naval Air Systems Command for fleet assessment and additional test assets for airworthiness and design verification. The NGJ-LB pods will fly on the EA-18G Growler and will support the Navy’s plan to replace the aging AN/ALQ-99 Tactical Jamming System. This first NGJ-LB contract to CPI Aero...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.